Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Maze Therapeutics, Inc.NASDAQ: MAZE
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow growth accelerates
Q1 FY2026 free cash flow of $39.21M (cash outflow) rose 31.5% year over year, ahead of the -277.7% change in trailing-twelve-month free cash flow. Sequentially, it rose 41.2% from the prior quarter. Over 3 fiscal years it compounded at +3.7% a year.
Context
- Free cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +31.5% holds above the trailing-twelve-month pace of -277.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (112.73M) USD
- Year-over-year change
- -250.7%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (112.73M) | -250.7% |
| FY2024 | 2024-12-31 | 74.81M | +185.7% |
| FY2023 | 2023-12-31 | (87.27M) | +13.7% |
| FY2022 | 2022-12-31 | (101.17M) | — |
Free Cash Flow vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -277.7% is the lowest of 8, against a peer median of +17.3%.
- Free cash flow amounts to 610.6% of revenue for MAZE, versus a peer median of 56.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $332.56M USD | -148.8% | — | 33.0% | |
| LTM Sep 2026 | $134.22M USD | +267.1% | -54.4% | 20.6% | |
| LTM Mar 2026 | $122.13M USD | -277.7% | +3.7% | 610.6% | |
| FY2025 | €101.22M EUR | +17.3% | +30.6% | 2257.9% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $88.63M USD | +64.1% | +31.4% | 859.1% |
SEPNSepterna, Inc. | LTM Sep 2026 | $77.59M USD | -175.2% | — | 80.6% |
| LTM Mar 2026 | $37.5M USD | -23.0% | -14.4% | 8.8% | |
| LTM Mar 2026 | $31.09M USD | +37.5% | +35.9% | — | |
| Peer median (excluding MAZE) | — | +17.3% | +30.6% | 56.8% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.